EP Patent

EP3646859A1 — Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin

Assigned to Boehringer Ingelheim International GmbH · Expires 2020-05-06 · 6y expired

What this patent protects

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

USPTO Abstract

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

Drugs covered by this patent

Patent Metadata

Patent number
EP3646859A1
Jurisdiction
EP
Classification
—
Expires
2020-05-06
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.